Envestnet Asset Management
VRDN icon

Envestnet Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Envestnet Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,519
Closed -$323K – 4970
2026
Q1 		$323K Buy
16,519
+1,615
+11% +$48K ﹤0.01% 4233
2025
Q4 		$464K Buy
14,904
+1,731
+13% +$47.5K ﹤0.01% 3750
2025
Q3 		$284K Sell
13,173
-182
-1% -$3.28K ﹤0.01% 4115
2025
Q2 		$187K Buy
+13,355
New +$181K ﹤0.01% 4250
2023
Q2 		– Sell
-8,414
Closed -$214K – 4091
2023
Q1 		$214K Buy
+8,414
New +$270K ﹤0.01% 3626

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Envestnet Asset Management's VRDN Position: Q2 2026 in Review

Envestnet Asset Management sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 16,519 shares — an estimated $323K sold.

Envestnet Asset Management first reported a position in VRDN in Q1 2023 and held it in 5 quarters. The position peaked at $464K in Q4 2025. 65 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Envestnet Asset Management reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Envestnet Asset Management sold 16,519 Viridian Therapeutics shares in Q2 2026, an estimated $323K.
  • Envestnet Asset Management first reported a position in Viridian Therapeutics in Q1 2023 and held it in 5 quarters.
  • Envestnet Asset Management's Viridian Therapeutics position peaked at $464K in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.